LeucoTox bridges outstanding developments in cancer research and the practical view of clinical oncologists to help address the critical need of developing novel treatment options for cancer patients. Over the past decade, the core researchers of LeucoTox have studied the mechanisms of cancer cell integrity and survival in a variety of cancer entities. This research has led to the development of a biological compound that interferes with the integrity and the survival of leukemic cells.
The team has generated a platform which allows us to construct, perturb, and observe model systems of leukemia in the laboratory, allowing for the understanding of the molecular mechanism of leukemia cell integrity at unprecedented breadth and scale. This approach is combined with tools of big data science in the context of a robst clinical perspective that were previously thought to be difficult to combine.
LeucoTox combines these technologies to develop a new approach to drug development in leukemia that might help us cure more patients, including elderly and frail patients due to a substantial reduction in toxic side effects of the compound.